(Q42862258)

8 November 2017

Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists (English)

1 reference

8 November 2017

0 references

0 references

Pierre L Triozzi

1

1 reference

8 November 2017

Wayne Aldrich

series ordinal

2

1 reference

8 November 2017

Selvarangan Ponnazhagan

series ordinal

3

1 reference

8 November 2017

language of work or name

English

0 references

publication date

27 October 2010

1 reference

8 November 2017

1 reference

8 November 2017

28

1 reference

8 November 2017

50

1 reference

8 November 2017

7837-7843

1 reference

Adenoassociated virus vectors for genetic immunization

8 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Boosting anti-idiotype immune response with recombinant AAV enhances tumour protection induced by gene gun vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Induction of an antitumoral immune response by wild-type adeno-associated virus type 2 in an in vivo model of pancreatic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Augmentation of antitumor activity of a recombinant adeno-associated virus carcinoembryonic antigen vaccine with plasmid adjuvant.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Genetic adjuvants for DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

TLR-TLR cross talk in human PBMC resulting in synergistic and antagonistic regulation of type-1 and 2 interferons, IL-12 and TNF-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Immune responses to malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Genetic immunization of mice with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Genomic stability of self-complementary adeno-associated virus 2 during early stages of transduction in mouse muscle in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

DNA and Adenoviral Vectors Encoding Carcinoembryonic Antigen Fused to Immunoenhancing Sequences Augment Antigen-Specific Immune Response and Confer Tumor Protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Induction of immune tolerance to FIX following muscular AAV gene transfer is AAV-dose/FIX-level dependent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

CpG motifs in bacterial DNA and their immune effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

IRF-7 is the master regulator of type-I interferon-dependent immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Regulation of immune responses by L-arginine metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Major role of local immune responses in antibody formation to factor IX in AAV gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Transgene expression levels and kinetics determine risk of humoral immune response modeled in factor IX knockout and missense mutant mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Synergism between CpG-containing oligodeoxynucleotides and IL-2 causes dramatic enhancement of vaccine-elicited CD8+ T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Induction of a systemic immune response by a polyvalent melanoma-associated antigen DNA vaccine for prevention and treatment of malignant melanoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Lipopolysaccharide and CpG DNA synergize for tumor necrosis factor-alpha production through activation of NF-kappaB.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Interaction of lipoteichoic acid and CpG-DNA during activation of innate immune cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Natural and synthetic TLR7 ligands inhibit CpG-A- and CpG-C-oligodeoxynucleotide-induced IFN-alpha production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Opposing effects of Toll-like receptor stimulation induce autoimmunity or tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Signaling through TLR7 enhances the immunosuppressive activity of murine CD4+CD25+ T regulatory cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

CpG-induced myeloid CD11b+Gr-1+ cells efficiently suppress T cell-mediated immunoreactivity and graft-versus-host disease in a murine model of allogeneic cell therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Dual role of polymorphonuclear neutrophils on the growth of Ehrlich ascites tumor (EAT) in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Vascular adhesion protein-1 enhances tumor growth by supporting recruitment of Gr-1+CD11b+ myeloid cells into tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Subsets of myeloid-derived suppressor cells in tumor-bearing mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Role of CD4(+)CD25(+) T regulatory cells in IL-2-induced vascular leak.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Enhanced transduction of mouse bone marrow-derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Targeting toll-like receptor signaling pathways for design of novel immune therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Of mice and men: species variations of Toll-like receptor expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Toll-like receptor control of the adaptive immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

Active immunization with tumor cells transduced by a novel AAV plasmid-based gene delivery system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.086

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2010.09.086

1 reference

release_7js7usnvsvhozg7iekbsi6phyy

8 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7js7usnvsvhozg7iekbsi6phyy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference